Robert H. Bates

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

The paper evaluates next-generation TB drug combinations in a mouse model, showing some regimens cure 90% of mice in under 2 months with faster sterilizing efficacy than existing treatments.

The paper evaluates 25 tuberculosis drug combinations in a mouse model, finding 15 combinations with T90 <5 months and three top combinations curing 90% of mice in <3 months.

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.